404 related articles for article (PubMed ID: 31356382)
1. Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A.
Erstad DJ; Ramsay IA; Jordan VC; Sojoodi M; Fuchs BC; Tanabe KK; Caravan P; Gale EM
Invest Radiol; 2019 Nov; 54(11):697-703. PubMed ID: 31356382
[TBL] [Abstract][Full Text] [Related]
2. Positron Emission Tomography-Magnetic Resonance Imaging Pharmacokinetics, In Vivo Biodistribution, and Whole-Body Elimination of Mn-PyC3A.
Zhou IY; Ramsay IA; Ay I; Pantazopoulos P; Rotile NJ; Wong A; Caravan P; Gale EM
Invest Radiol; 2021 Apr; 56(4):261-270. PubMed ID: 33136686
[TBL] [Abstract][Full Text] [Related]
3. A Manganese-based Alternative to Gadolinium: Contrast-enhanced MR Angiography, Excretion, Pharmacokinetics, and Metabolism.
Gale EM; Wey HY; Ramsay I; Yen YF; Sosnovik DE; Caravan P
Radiology; 2018 Mar; 286(3):865-872. PubMed ID: 29117483
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Jan; 31(1):11-6. PubMed ID: 8850360
[TBL] [Abstract][Full Text] [Related]
5. A Manganese Alternative to Gadolinium for MRI Contrast.
Gale EM; Atanasova IP; Blasi F; Ay I; Caravan P
J Am Chem Soc; 2015 Dec; 137(49):15548-57. PubMed ID: 26588204
[TBL] [Abstract][Full Text] [Related]
6. Dynamic contrast-enhanced MRI of the liver in Mrp2-deficient rats using the hepatobiliary contrast agent Gd-EOB-DTPA.
Saito S; Obata A; Kashiwagi Y; Abe K; Murase K
Invest Radiol; 2013 Jul; 48(7):548-53. PubMed ID: 23442774
[TBL] [Abstract][Full Text] [Related]
7. A New OATP-Mediated Hepatobiliary-Specific Mn(II)-Based MRI Contrast Agent for Hepatocellular Carcinoma in Mice: A Comparison With Gd-EOB-DTPA.
Xue Y; Xiao B; Xia Z; Dai L; Xia Q; Zhong L; Zhu C; Zhu J
J Magn Reson Imaging; 2023 Sep; 58(3):926-933. PubMed ID: 36609994
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine.
Kiryu S; Inoue Y; Watanabe M; Izawa K; Shimada M; Tojo A; Yoshikawa K; Ohtomo K
Magn Reson Imaging; 2009 Jan; 27(1):101-7. PubMed ID: 18599243
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Gd-EOB-DTPA and Gd-DTPA for contrast-enhanced MR imaging of liver tumors.
Clemént O; Mühler A; Vexler VS; Kuwatsuru R; Berthezène Y; Rosenau W; Brasch RC
J Magn Reson Imaging; 1993; 3(1):71-7. PubMed ID: 8428104
[TBL] [Abstract][Full Text] [Related]
10. Comparison between Gd-DTPA, Gd-EOB-DTPA, and Mn-DPDP in induced HCC in rats: a correlation study of MR imaging, microangiography, and histology.
Marchal G; Zhang X; Ni Y; Van Hecke P; Yu J; Baert AL
Magn Reson Imaging; 1993; 11(5):665-74. PubMed ID: 8345781
[TBL] [Abstract][Full Text] [Related]
11. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC
Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739
[TBL] [Abstract][Full Text] [Related]
12. Chimeric mouse model for MRI contrast agent evaluation.
Mir FF; Tomaszewski RP; Shuboni-Mulligan DD; Mallett CL; Hix JML; Ether ND; Shapiro EM
Magn Reson Med; 2019 Jul; 82(1):387-394. PubMed ID: 30874333
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid.
Jia J; Puls D; Oswald S; Jedlitschky G; Kühn JP; Weitschies W; Hosten N; Siegmund W; Keiser M
Invest Radiol; 2014 Feb; 49(2):78-86. PubMed ID: 24056116
[TBL] [Abstract][Full Text] [Related]
14. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA.
Runge VM
J Comput Assist Tomogr; 1998; 22(4):643-50. PubMed ID: 9676461
[TBL] [Abstract][Full Text] [Related]
15. Hepatic kinetics and magnetic resonance imaging of gadolinium-EOB-DTPA in dogs.
Benness G; Khangure M; Morris I; Warwick A; Burrows P; Vogler H; Weinmann HJ
Invest Radiol; 1996 Apr; 31(4):211-7. PubMed ID: 8721960
[TBL] [Abstract][Full Text] [Related]
16. [Renal enhancement and excretion of the hepatobiliary contrast agent Gd-EOB-DTPA].
Zangos S; Hammerstingl R; Mack MG; Straub R; Engelmann K; Eichler K; Balzer T; Vogl TJ
Rofo; 2001 Nov; 173(11):1034-40. PubMed ID: 11704914
[TBL] [Abstract][Full Text] [Related]
17. In vivo magnetic resonance imaging of mice liver tumors using a new gadolinium-based contrast agent.
Chen SH; Kuo YT; Cheng TL; Chen CY; Chiu YY; Lai JJ; Chang CC; Jaw TS; Wang YM; Liu GC
Kaohsiung J Med Sci; 2013 May; 29(5):246-53. PubMed ID: 23639510
[TBL] [Abstract][Full Text] [Related]
18. Development of Bifunctional Gadolinium-Labeled Superparamagnetic Nanoparticles (Gd-MnMEIO) for In Vivo MR Imaging of the Liver in an Animal Model.
Kuo YT; Chen CY; Liu GC; Wang YM
PLoS One; 2016; 11(2):e0148695. PubMed ID: 26886558
[TBL] [Abstract][Full Text] [Related]
19. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the link between quantitative biexponential diffusion-weighted imaging and contrast-enhanced MRI in the liver.
Dijkstra H; Oudkerk M; Kappert P; Sijens PE
Magn Reson Imaging; 2017 May; 38():47-53. PubMed ID: 27993534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
